↑ トップへ　← 戻る

 Drug（薬物リスト） DrugBank | All Description Patterns

   e.g. "Sirolimus", "アダリムマブ"

A　B　C　D　E　F　G　H　 I 　J　K　L　M　N　O　P　Q　R　S　T　U　V　W　X　Y　Z　other

433 / 12,170 descriptions found* Show info (disease name, etc.) on mouse-over.
 No.   薬物名（臨床試験情報から抽出）   DrugBank   KEGG DRUG *   KEGG GENES *   KEGG PATHWAY   指定難病告示番号 * 
 1   (-)-epicatechin   Epicatechin   -   -   -   2件:
86,
113 
 2   (pyr1)apelin-13   -   -   -   -   1件:
86 
 3   11c acetate   Acetate   -   -   -   1件:
86 
 4   11c-acetate   Acetate   -   -   -   3件:
13,
86,
88 
 5   120 mg sodium nitrite inhalation solution   Nitrite   -   -   -   1件:
86 
 6   15 mg sodium nitrite inhalation solution   Nitrite   -   -   -   1件:
86 
 7   150mg cxa-10   -   -   -   -   1件:
86 
 8   2-(4-[5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy)-n-(methylsulfonyl)actamide   -   -   -   -   1件:
86 
 9   20 mg sildenafil citrate by mouth   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 10   25% mtd sodium nitrite inhalation solution   Nitrite   -   -   -   1件:
86 
 11   45 mg sodium nitrite inhalation solution   Nitrite   -   -   -   1件:
86 
 12   4au76   -   -   -   -   1件:
86 
 13   66215-101   -   -   -   -   1件:
86 
 14   6r-bh4   Sapropterin   D08505   -   -   3件:
86,
124,
240 
 15   75mg cxa-10   -   -   -   -   1件:
86 
 16   90 mg sodium nitrite inhalation solution   Nitrite   -   -   -   1件:
86 
 17   [11c]-gsk2256098 500 mbq   -   -   -   -   1件:
86 
 18   [18f] fes   -   -   -   -   1件:
86 
 19   [18f]fluoro-2-deoxy-2-d-glucose   D-glucose   D00009   -   -   2件:
86,
88 
 20   Abi-009, nab-rapamycin, albumin-bound rapamycin   Sirolimus   D00753   1件: MTOR   43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   1件:
86 
 21   Access program - sildenafil citrate, viagra, revatio   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 22   Acetaminophen   Acetaminophen   D00217   2件: PTGS1, PTGS2   21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   11件:
13,
34,
35,
46,
49,
51,
70,
86,
231,
256,
271 
 23   Acetate   Acetate   -   -   -   40件:
1,
2,
6,
10,
13,
35,
40,
46,
49,
51,
60,
64,
70,
71,
73,
75,
76,
78,
81,
83,
85,
86,
88,
90,
96,
97,
113,
145,
156,
162,
171,
206,
222,
224,
225,
235,
265,
288,
298,
299 
 24   Act-050089   -   -   -   -   1件:
86 
 25   Act-050089 (ro 61-0612)   -   -   -   -   1件:
86 
 26   Act-064992   -   -   -   -   4件:
85,
86,
88,
210 
 27   Act-064992d   -   -   -   -   1件:
86 
 28   Act-293987   -   -   -   -   2件:
51,
86 
 29   Act-293987 (ns-304)   -   -   -   -   1件:
86 
 30   Act-385781a   -   -   -   -   1件:
86 
 31   Act-385781a (actelion epoprostenol)   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 32   Adcirca   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 33   Adempas   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   4件:
51,
86,
225,
299 
 34   Adempas (riociguat, bay63-2521)   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   1件:
86 
 35   Adempas 0.5 mg   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   2件:
86,
299 
 36   Adempas 1.0 mg   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   2件:
86,
299 
 37   Adempas 1.5 mg   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   1件:
86 
 38   Adempas 2.0 mg   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   2件:
86,
299 
 39   Adempas 2.5 mg   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   1件:
86 
 40   Adempas®   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   2件:
86,
88 
 41   Aerosolized iloprost   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 42   Air001   -   -   -   -   1件:
86 
 43   Air001 (sodium nitrite inhalation solution)   Nitrite   -   -   -   1件:
86 
 44   Air001 inhalation solution   -   -   -   -   1件:
86 
 45   Air001 inhalation solution (expansion arm)   -   -   -   -   1件:
86 
 46   Albuterol   Salbutamol   D02147   1件: ADRB2   8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   8件:
12,
13,
86,
89,
113,
231,
256,
299 
 47   Albuterol first   Salbutamol   D02147   1件: ADRB2   8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 48   Albuterol.   Salbutamol   D02147   1件: ADRB2   8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 49   Allogeneic human cardiosphere-derived stem cells   -   -   -   -   1件:
86 
 50   Ambrisentan   Ambrisentan   D07077   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   6件:
51,
84,
85,
86,
88,
211 
 51   Ambrisentan - high dose   Ambrisentan   D07077   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 52   Ambrisentan - low dose   Ambrisentan   D07077   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 53   Ambrisentan 5 mg film-coated tablets   Ambrisentan   D07077   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 54   Ambrisentan plus spironolactone   Spironolactone   D00443   1件: NR3C2   1件: Aldosterone-regulated sodium reabsorption   1件:
86 
 55   Amn107   -   -   -   -   2件:
34,
86 
 56   Anakinra   Anakinra   D02934   2件: IL1R1, IL1R2   15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer   15件:
2,
13,
15,
19,
37,
41,
46,
49,
50,
56,
84,
86,
106,
107,
299 
 57   Anastrozole   Anastrozole   D00960   1件: CYP19A1   3件: Metabolic pathways, Ovarian steroidogenesis, Steroid hormone biosynthesis   3件:
78,
86,
193 
 58   Angiotensin   Angiotensin ii   D00150, D02014   2件: AGTR1, AGTR2   14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   7件:
17,
19,
46,
66,
86,
222,
224 
 59   Apabetalone   Apabetalone   D11131   -   -   1件:
86 
 60   Apd811   -   -   -   -   1件:
86 
 61   Apelin   -   -   -   -   1件:
86 
 62   Ar392830   -   -   -   -   1件:
86 
 63   Aspirin   Acetylsalicylic acid   D00109   2件: PTGS1, PTGS2   21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   10件:
13,
22,
34,
46,
49,
51,
86,
113,
158,
231 
 64   Assigned pulmonary hypertension medication   -   -   -   -   1件:
86 
 65   Autologous epcs transfected   -   -   -   -   1件:
86 
 66   Autologous epcs transfected with human enos   -   -   -   -   1件:
86 
 67   Aviptadil   Aviptadil   -   -   -   4件:
49,
51,
85,
86 
 68   Bardoxolone   Bardoxolone   D09584   -   -   7件:
66,
67,
84,
85,
86,
218,
222 
 69   Bardoxolone methyl   Bardoxolone methyl   D09585   -   -   7件:
66,
67,
84,
85,
86,
218,
222 
 70   Bardoxolone methyl capsules   Bardoxolone methyl   D09585   -   -   4件:
66,
67,
86,
222 
 71   Bay 63-2521   -   -   -   -   2件:
86,
88 
 72   Bay 63-2521 0.06 %   -   -   -   -   1件:
86 
 73   Bay 63-2521 0.3 %   -   -   -   -   1件:
86 
 74   Bay 63-2521 ir tablets 0.5 mg   -   -   -   -   1件:
86 
 75   Bay 63-2521 ir tablets 1 mg   -   -   -   -   1件:
86 
 76   Bay 63-2521 ir tablets 1.0 mg   -   -   -   -   1件:
86 
 77   Bay 63-2521 ir tablets 1.5 mg   -   -   -   -   1件:
86 
 78   Bay 63-2521 ir tablets 2.0 mg   -   -   -   -   1件:
86 
 79   Bay 63-2521 ir tablets 2.5 mg   -   -   -   -   1件:
86 
 80   Bay 63-2521 tablet   -   -   -   -   1件:
86 
 81   Bay 63-2521 tablets 0.5 mg   -   -   -   -   2件:
86,
88 
 82   Bay 63-2521 tablets 1 mg   -   -   -   -   2件:
86,
88 
 83   Bay 63-2521 tablets 1.5 mg   -   -   -   -   2件:
86,
88 
 84   Bay 63-2521 tablets 2 mg   -   -   -   -   2件:
86,
88 
 85   Bay 63-2521 tablets 2.5 mg   -   -   -   -   2件:
86,
88 
 86   Bay q 6256   -   -   -   -   1件:
86 
 87   Bay1237592   -   -   -   -   2件:
86,
88 
 88   Bay63-2521   -   -   -   -   3件:
51,
86,
299 
 89   Beetroot juice   -   -   -   -   1件:
86 
 90   Benzbromaron   Benzbromarone   D01056   -   -   1件:
86 
 91   Benzbromaron al   Benzbromarone   D01056   -   -   1件:
86 
 92   Benzbromarone   Benzbromarone   D01056   -   -   1件:
86 
 93   Beraprost   Beraprost   D02720   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 94   Beraprost sodium   Beraprost   D02720   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 95   Beraprost sodium 314d modified release tablets   Beraprost   D02720   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 96   Beraprost sodium modified release   Beraprost   D02720   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 97   Bevacizumab   Bevacizumab   D06409   1件: VEGFA   21件: AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway   9件:
13,
34,
85,
86,
87,
89,
227,
280,
331 
 98   Bia 5-1058   -   -   -   -   1件:
86 
 99   Bia-5-1058   -   -   -   -   1件:
86 
 100   Biological dmards   -   -   -   -   1件:
86 
 101   Bisoprolol   Bisoprolol   D00634, D02342   1件: ADRB1   10件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   3件:
67,
86,
113 
 102   Blood test   -   -   -   -   5件:
36,
86,
113,
162,
299 
 103   Bosentan   Bosentan   D01227, D07538   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   9件:
13,
41,
47,
51,
84,
85,
86,
88,
210 
 104   Bosentan administration   Bosentan   D01227, D07538   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 105   Bosentan and sildenafil   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 106   Bosentan monohydrat   Bosentan   D01227, D07538   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 107   Bosentan monohydrate   Bosentan   D01227, D07538   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   4件:
51,
84,
86,
88 
 108   Bosentan, ambrisentan   Ambrisentan   D07077   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 109   Bps-314d-mr   -   -   -   -   1件:
86 
 110   Bps-mr   -   -   -   -   1件:
86 
 111   Bsf 208075   -   -   -   -   1件:
86 
 112   C07ab07   -   -   -   -   1件:
86 
 113   C225   Cetuximab   D03455   1件: EGFR   45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis   2件:
51,
86 
 114   Capsaicin   Capsaicin   D00250   1件: TRPV1   2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction   6件:
2,
6,
19,
86,
113,
226 
 115   Captopril   Captopril   D00251   1件: ACE   4件: Chagas disease (American trypanosomiasis), Hypertrophic cardiomyopathy (HCM), Renin secretion, Renin-angiotensin system   2件:
17,
86 
 116   Carbon   Activated charcoal   D03251   -   -   7件:
6,
46,
85,
86,
96,
97,
298 
 117   Carbon monoxide   Carbon monoxide   D09706   -   -   3件:
85,
86,
298 
 118   Carvedilol   Carvedilol   D00255, D03415   5件: ADRA1A, ADRA1B, ADRA1D, ADRB1, ADRB2   12件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy (DCM), Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   4件:
6,
57,
86,
113 
 119   Cetuximab   Cetuximab   D03455   1件: EGFR   45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis   5件:
34,
51,
86,
89,
331 
 120   Chlorhexidine   Chlorhexidine   D00858, D01345, D03463, D07668   -   -   2件:
86,
299 
 121   Cialis   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   2件:
51,
86 
 122   Cialis 10 mg film-coated tablets   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   2件:
86,
113 
 123   Cialis 2.5 mg film-coated tablets   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   2件:
86,
113 
 124   Cialis 20 mg film-coated tablets   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   2件:
86,
113 
 125   Cialis 5 mg film-coated tablets   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   2件:
86,
113 
 126   Cicletanine   Cicletanine   D03487   -   -   1件:
86 
 127   Citrulline   L-citrulline   D07706   -   -   2件:
86,
113 
 128   Clopidogrel   Clopidogrel   D00769, D07729, D10823, D10824   1件: P2RY12   1件: Platelet activation   2件:
49,
86 
 129   Coenzyme q-10   Ubidecarenone   D01065   -   -   1件:
86 
 130   Coenzyme q-10 in normal control subjects   Ubidecarenone   D01065   -   -   1件:
86 
 131   Coenzyme q-10 in pulmonary hypertension subjects   Ubidecarenone   D01065   -   -   1件:
86 
 132   Commercial ventavis® (iloprost)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 133   Conivaptan   Conivaptan   D01236, D07748   2件: AVPR1A, AVPR2   5件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vascular smooth muscle contraction, Vasopressin-regulated water reabsorption   1件:
86 
 134   Current marketed flolan (epoprostenol sodium)   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 135   Cxa-10   -   -   -   -   2件:
86,
222 
 136   D-glucose   D-glucose   D00009   -   -   3件:
49,
86,
88 
 137   Dhea   Prasterone   D08409   3件: AR, ESR1, ESR2   11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway   3件:
49,
86,
96 
 138   Dhea tablet   Prasterone   D08409   3件: AR, ESR1, ESR2   11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway   1件:
86 
 139   Dichloroacetate   Dichloroacetic acid   -   -   -   1件:
86 
 140   Dichloroacetate sodium   Dichloroacetic acid   -   -   -   1件:
86 
 141   Diltiazem   Diltiazem   D00616, D03830, D07845   4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   3件:
58,
86,
130 
 142   Diltiazem hydrochloride   Diltiazem   D00616, D03830, D07845   4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 143   Dimethyl fumarate   Dimethyl fumarate   D03846   1件: KEAP1   4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis   3件:
13,
51,
86 
 144   Dimethyl fumarate (dmf)   Dimethyl fumarate   D03846   1件: KEAP1   4件: Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Pathways in cancer, Ubiquitin mediated proteolysis   3件:
13,
51,
86 
 145   Diphenhydramine   Diphenhydramine   D00300, D00669, D02419, D03285, D03360, D03854   1件: HRH1   3件: Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction   5件:
49,
51,
70,
86,
256 
 146   Efi/act-385781a   -   -   -   -   1件:
86 
 147   Elafin   Elafin   -   -   -   1件:
86 
 148   Endothelin receptor antagonist therapy   -   -   -   -   1件:
86 
 149   Endothelin-3   -   -   -   -   1件:
86 
 150   Enos transfected epcs will be delivered via a pa line   -   -   -   -   1件:
86 
 151   Epicatechin   Epicatechin   -   -   -   2件:
86,
113 
 152   Epoprostenol   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 153   Epoprostenol for injection   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 154   Epoprostenol sodium   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 155   Epoprostenol-actelion   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 156   Era and pde-5i (sildenafil, tadalafil, bosentan, macitentan)   Macitentan, Sildenafil   D02229, D08514, D10135   3件: EDNRA, EDNRB, PDE5A   11件: Calcium signaling pathway, Melanogenesis, Metabolic pathways, Neuroactive ligand-receptor interaction, Pathways in cancer, Purine metabolism, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 157   Erbitux   Cetuximab   D03455   1件: EGFR   45件: Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis   2件:
51,
86 
 158   Esomeprazole   Esomeprazole   D01984, D04056, D07917, D09339   2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   6件:
6,
46,
86,
98,
298,
299 
 159   Eutonic treprostinil solution   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 160   Famotidine   Famotidine   D00318   1件: HRH2   3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction   3件:
6,
46,
86 
 161   Famotidine 20 mg   Famotidine   D00318   1件: HRH2   3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction   1件:
86 
 162   Fdc macitentan/tadalafil   Macitentan   D10135   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 163   Ferinject   -   -   -   -   1件:
86 
 164   Ferinject or cosmofer   -   -   -   -   1件:
86 
 165   Ferric carboxymaltose   Ferric carboxymaltose   D08920   -   -   4件:
86,
96,
97,
299 
 166   Ferricarboxymaltose   -   -   -   -   1件:
86 
 167   Fk506   Tacrolimus   D00107, D08556   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   2件:
86,
222 
 168   Fk506 level 2-3 ng/ml   Tacrolimus   D00107, D08556   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 169   Fk506 level 3-5 ng/ml   Tacrolimus   D00107, D08556   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 170   Fk506 level < 2 ng/ml   Tacrolimus   D00107, D08556   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 171   Flolan injection with currently marketed diluent   -   -   -   -   1件:
86 
 172   Flolan injection with reformulated diluent   -   -   -   -   1件:
86 
 173   Flolan tm and glycine diluent   Glycine   D00011   -   -   1件:
86 
 174   Flolan®   -   -   -   -   1件:
86 
 175   Flolan™ and glycine diluent   Glycine   D00011   -   -   1件:
86 
 176   Fluoxetine   Fluoxetine   D00326, D00823   1件: SLC6A4   2件: Serotonergic synapse, Synaptic vesicle cycle   4件:
13,
17,
78,
86 
 177   Fulvestrant   Fulvestrant   D01161   2件: ESR1, ESR2   9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway   1件:
86 
 178   Gb002   -   -   -   -   1件:
86 
 179   Glivec   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   2件:
51,
86 
 180   Glivec 100 mg comprimidos recubiertos con película   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   2件:
34,
86 
 181   Glivec®   -   -   -   -   1件:
86 
 182   Glivec® 100 mg filmtabletten   -   -   -   -   1件:
86 
 183   Glycine   Glycine   D00011   -   -   4件:
35,
86,
226,
299 
 184   Gsk1325760   -   -   -   -   2件:
86,
88 
 185   Gsk1325760a   -   -   -   -   1件:
86 
 186   Gsk2586881   -   -   -   -   1件:
86 
 187   Hgp1206   -   -   -   -   1件:
86 
 188   Hydroxyurea   Hydroxyurea   D00341   1件: RRM2   6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway   8件:
3,
13,
19,
20,
65,
85,
86,
284 
 189   Hypotonictreprostinil solution   -   -   -   -   1件:
86 
 190   I.v. selexipag   Selexipag   D09994   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 191   Ifetroban   Ifetroban   D04500   1件: TBXA2R   3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation   3件:
51,
86,
113 
 192   Ilomedin 20   -   -   -   -   1件:
86 
 193   Ilomedin 20 [20 µg / ml]   -   -   -   -   1件:
86 
 194   Iloprost   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   4件:
51,
84,
85,
86 
 195   Iloprost (5 µg)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 196   Iloprost (ventavis bayq6256)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 197   Iloprost (ventavis inhaled, bayq6256)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 198   Iloprost (ventavis, bayq 6256)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 199   Iloprost (ventavis, bayq6256)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 200   Iloprost (ventavis®)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 201   Iloprost inhalation solution (ventavis)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   2件:
85,
86 
 202   Iloprost pd-15   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 203   Iloprost pd-6   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 204   Iloprost,(ventavis, bayq6256)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 205   Imatinib   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   11件:
13,
28,
34,
35,
46,
51,
85,
86,
87,
89,
162 
 206   Imatinib mesilate   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   2件:
13,
86 
 207   Imatinib mesylate   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   5件:
13,
28,
34,
51,
86 
 208   Inhaled dry powder treprostinil (liq861)   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 209   Inhaled iloprost (ventavis, bayq6256)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 210   Inhaled nitric oxide   Nitric oxide   D00074   -   -   2件:
85,
86 
 211   Inhaled nitric oxide & inopulse delivery   Nitric oxide   D00074   -   -   1件:
86 
 212   Inhaled nitric oxide 75 mcg/kg ibw/hr   Nitric oxide   D00074   -   -   2件:
85,
86 
 213   Inhaled no with pulsed delivery   -   -   -   -   1件:
86 
 214   Inhaled prostacyclin   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 215   Inhaled treprostinil   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   2件:
84,
86 
 216   Intravenous administration of ferric carboxymaltose   Ferric carboxymaltose   D08920   -   -   1件:
86 
 217   Intravenous treprostinil   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 218   Intravenous/subcutaneous treprostinil   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 219   Ipratropium   Ipratropium   D02212   5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5   11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway   2件:
6,
86 
 220   Iron   Iron   -   -   -   7件:
13,
62,
86,
96,
97,
254,
284 
 221   Iron supplement   Iron   -   -   -   1件:
86 
 222   Jtt-251   -   -   -   -   1件:
86 
 223   Kar5585 capsules   -   -   -   -   1件:
86 
 224   L-citrulline   L-citrulline   D07706   -   -   2件:
86,
113 
 225   L-citrulline malate   L-citrulline   D07706   -   -   1件:
86 
 226   Levitra   Vardenafil   D02731, D03260, D08668   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   2件:
13,
86 
 227   Lidocaine   Lidocaine   D00358, D02086, D08127   5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A   3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction   8件:
6,
13,
46,
86,
168,
226,
231,
256 
 228   Liq861 inhaled treprostinil   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 229   Lisuride   Lisuride   D01462, D08132   3件: DRD2, DRD3, DRD4   8件: Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway   2件:
6,
86 
 230   Lloprost(ventavis,bayq6252, 10 µg/ml)   -   -   -   -   1件:
86 
 231   Lloprost(ventavis,bayq6252, 20 µg/ml)   -   -   -   -   1件:
86 
 232   Ly450190   -   -   -   -   1件:
86 
 233   Macitentan   Macitentan   D10135   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   5件:
51,
85,
86,
88,
210 
 234   Macitentan 10 mg   Macitentan   D10135   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   2件:
86,
88 
 235   Macitentan 10 mg tablet, once daily.   Macitentan   D10135   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 236   Macitentan group   Macitentan   D10135   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 237   Md-711   -   -   -   -   1件:
86 
 238   Medical air   Medical air   -   -   -   3件:
85,
86,
193 
 239   Metformin   Metformin   D00944, D04966   2件: PRKAA1, PRKAA2   19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy (HCM), Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease (NAFLD), Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway   16件:
6,
13,
46,
49,
67,
75,
77,
81,
86,
113,
158,
206,
225,
233,
265,
285 
 240   Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo   -   -   -   -   1件:
86 
 241   Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb   -   -   -   -   2件:
86,
88 
 242   Methyl [4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1h-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]meth   -   -   -   -   2件:
86,
88 
 243   Methylprednisolone   Methylprednisolone   D00407, D00751, D00979, D05000, D05001, D05002   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296 
 244   Mk-5475   -   -   -   -   1件:
86 
 245   Mk-8892   -   -   -   -   1件:
86 
 246   Morphine   Morphine   D00842, D02271, D08233   1件: OPRM1   3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction   4件:
36,
46,
70,
86 
 247   Morphine sulfate   Morphine   D00842, D02271, D08233   1件: OPRM1   3件: Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction   2件:
46,
86 
 248   Moxifloxacin   Moxifloxacin   D00874, D08237   -   -   8件:
2,
6,
46,
49,
85,
86,
240,
299 
 249   Moxifloxacin 400 mg   Moxifloxacin   D00874, D08237   -   -   1件:
86 
 250   Multihance   Gadobenic acid   D04283, D08018   -   -   2件:
86,
88 
 251   Nebulized combination ipratropium bromide with salbutamol   Ipratropium   D02212   5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5   11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway   1件:
86 
 252   Nebulized ipratropium bromide   Ipratropium   D02212   5件: CHRM1, CHRM2, CHRM3, CHRM4, CHRM5   11件: Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway   1件:
86 
 253   New thermo stable formulation of epoprostenol sodium   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 254   Nicardipine   Nicardipine   D00617, D08270   4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   2件:
70,
86 
 255   Nilotinib   Nilotinib   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   5件:
6,
8,
34,
51,
86 
 256   Nitric oxide   Nitric oxide   D00074   -   -   7件:
46,
85,
86,
98,
251,
294,
299 
 257   Nitric oxide for inhalation   Nitric oxide   D00074   -   -   2件:
86,
299 
 258   Nitric oxide generated by the geno nitrosyl delivery system   Nitric oxide   D00074   -   -   1件:
86 
 259   Nitric oxide plus oxygen   Nitric oxide   D00074   -   -   1件:
86 
 260   Nitrite   Nitrite   -   -   -   2件:
86,
299 
 261   Nitrosyl   Nitric oxide   D00074   -   -   1件:
86 
 262   Non-biologic dmards   -   -   -   -   1件:
86 
 263   Ns-304   -   -   -   -   3件:
70,
86,
88 
 264   Null   -   -   -   -   17件:
6,
13,
14,
15,
28,
37,
46,
49,
51,
63,
86,
90,
96,
97,
107,
145,
271 
 265   Nx1011   -   -   -   -   1件:
86 
 266   Observational study with patients treated with tracleer, ventavis, veletri, opsumit and/or uptravi   -   -   -   -   1件:
86 
 267   Olaparib   Olaparib   D09730   3件: PARP1, PARP2, PARP3   4件: Apoptosis, Base excision repair, NF-kappa B signaling pathway, Necroptosis   1件:
86 
 268   Opsumit   Macitentan   D10135   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   2件:
86,
88 
 269   Opsumit (macitentan)   Macitentan   D10135   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 270   Opsumit®   -   -   -   -   3件:
86,
88,
210 
 271   Oral anticoagulant treatment   -   -   -   -   1件:
86 
 272   Oral era   -   -   -   -   1件:
86 
 273   Oral ifetroban   Ifetroban   D04500   1件: TBXA2R   3件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation   2件:
51,
86 
 274   Oral pde5 inhibitors   -   -   -   -   1件:
86 
 275   Oral selexipag (uptravi)   Selexipag   D09994   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 276   Oral sildenafil   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 277   Oral treprostinil   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   2件:
51,
86 
 278   Oral treprostinil (ut-15c) sustained release tablets   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 279   Oxygen   Oxygen   D00003   -   -   14件:
46,
49,
70,
84,
85,
86,
88,
90,
96,
97,
193,
226,
299,
330 
 280   Oxygen supplementation   Oxygen   D00003   -   -   1件:
86 
 281   Pah medication   -   -   -   -   1件:
86 
 282   Parenteral remodulin (treprostinil) injection   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 283   Pb1046   -   -   -   -   1件:
86 
 284   Pb1046 injection   -   -   -   -   2件:
86,
113 
 285   Pb1046 subcutaneous injection   -   -   -   -   1件:
86 
 286   Pf-00489791   -   -   -   -   1件:
86 
 287   Ph-combination therapy   -   -   -   -   2件:
86,
88 
 288   Ph-monotherapy   -   -   -   -   2件:
86,
88 
 289   Pioglitazone   Pioglitazone   D00945, D08378   1件: PPARG   9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer   17件:
2,
6,
13,
15,
20,
46,
49,
65,
67,
78,
81,
86,
96,
229,
265,
298,
299 
 290   Placebo   -   -   -   -   20件:
3,
6,
13,
14,
40,
46,
49,
50,
51,
66,
67,
79,
85,
86,
88,
96,
97,
144,
149,
226 
 291   Plx-pad   -   -   -   -   1件:
86 
 292   Prednisone   Prednisone   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   43件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331 
 293   Prostacyclin   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 294   Puri-nethol   Mercaptopurine   D00161, D04931   1件: HPRT1   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   1件:
86 
 295   Qcc374   -   -   -   -   1件:
86 
 296   Qcc374 0.015 mg   -   -   -   -   1件:
86 
 297   Qcc374 0.06 mg   -   -   -   -   1件:
86 
 298   Qti571   -   -   -   -   1件:
86 
 299   Qutenza   Capsaicin   D00250   1件: TRPV1   2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction   1件:
86 
 300   Qutenza (8% capsaicin)   Capsaicin   D00250   1件: TRPV1   2件: Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction   1件:
86 
 301   Ralinepag   Ralinepag   D10725   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 302   Ranolazine   Ranolazine   D05700, D05701   -   -   6件:
2,
58,
86,
113,
114,
130 
 303   Rapamycin   Sirolimus   D00753   1件: MTOR   43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   16件:
2,
15,
34,
35,
46,
49,
51,
60,
61,
67,
86,
89,
158,
256,
278,
279 
 304   Rapid dose titration group of subcutaneous treprostinil   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 305   Recombinant human angiotensin-converting enzyme 2 (ace2), apn01   Angiotensin ii   D00150, D02014   2件: AGTR1, AGTR2   14件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   1件:
86 
 306   Remodulin   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 307   Remodulin (treprostinil sodium)   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 308   Remodulin® (treprostinil) 1 mg/ml solution for infusion   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 309   Remodulin® (treprostinil) 10 mg/ml solution for infusion   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 310   Remodulin® (treprostinil) 2.5 mg/ml solution for infusion   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 311   Remodulin® (treprostinil) 5 mg/ml solution for infusion   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 312   Revatio   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   2件:
85,
86 
 313   Revatio inyectable   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 314   Revatio oral   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 315   Revatio ® 20 mg film-coated tablets   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 316   Revatio®   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 317   Riciguat group   -   -   -   -   1件:
86 
 318   Rifampin   Rifampicin   D00211   -   -   5件:
6,
13,
84,
86,
299 
 319   Riociguat   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   6件:
51,
84,
86,
88,
225,
299 
 320   Riociguat (adempas, bay63-2521)   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   3件:
51,
86,
88 
 321   Riociguat (bay63-2521)   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   1件:
86 
 322   Riociguat granules 0.3% for oral application   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   1件:
86 
 323   Riociguat oral product   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   1件:
86 
 324   Riociguat pill   Riociguat   D09572   3件: GUCY1A1, GUCY1A2, GUCY1B1   11件: Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway   1件:
86 
 325   Ritonavir   Ritonavir   D00427   -   -   4件:
2,
86,
130,
265 
 326   Rituximab   Rituximab   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331 
 327   Ro 47-0203   Bosentan   D01227, D07538   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   4件:
51,
85,
86,
88 
 328   Ro 47-0203 / act-050088   Bosentan   D01227, D07538   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 329   Ro-47-0203   Bosentan   D01227, D07538   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 330   Ro-47-0203/029   Bosentan   D01227, D07538   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 331   Ro47-0203   -   -   -   -   1件:
86 
 332   Ro47-0203 / act-050088   -   -   -   -   2件:
51,
86 
 333   Roactemra   -   -   -   -   5件:
41,
46,
51,
86,
107 
 334   Rvg 33865   -   -   -   -   1件:
86 
 335   Rvt-1201   -   -   -   -   1件:
86 
 336   Salbutamol   Salbutamol   D02147   1件: ADRB2   8件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway   8件:
3,
11,
49,
85,
86,
228,
256,
299 
 337   Saline   Sodium chloride   D02056   -   -   10件:
6,
13,
17,
53,
67,
78,
86,
97,
168,
299 
 338   Sapropterin   Sapropterin   D08505   -   -   3件:
86,
124,
240 
 339   Sapropterin dihydrochloride (6r-bh4)   Sapropterin   D08505   -   -   1件:
86 
 340   Saquinavir   Saquinavir   D00429, D01160   -   -   2件:
86,
265 
 341   Saquinavir and ritonavir   Saquinavir   D00429, D01160   -   -   1件:
86 
 342   Selexipag   Selexipag   D09994   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   5件:
51,
70,
84,
86,
88 
 343   Selexipag (uptravi)   Selexipag   D09994   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 344   Selonsertib   Selonsertib   D10988   1件: MAP3K5   12件: Amyotrophic lateral sclerosis (ALS), Apoptosis, Fluid shear stress and atherosclerosis, MAPK signaling pathway, Neurotrophin signaling pathway, Non-alcoholic fatty liver disease (NAFLD), Platinum drug resistance, Protein processing in endoplasmic reticulum, Sphingolipid signaling pathway, TNF signaling pathway, Thermogenesis, Tight junction   1件:
86 
 345   Serine   Serine   D00016   -   -   3件:
2,
6,
86 
 346   Sham o2 (medical air)   Medical air   -   -   -   1件:
86 
 347   Sildenafil   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   15件:
6,
46,
50,
51,
85,
86,
113,
210,
211,
212,
225,
226,
278,
294,
299 
 348   Sildenafil (as citrate)   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 349   Sildenafil (revatio)   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 350   Sildenafil (revatio) 20 mg tid   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 351   Sildenafil 20mg   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   2件:
51,
86 
 352   Sildenafil 20mg and bosentan 62.5mg   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   2件:
51,
86 
 353   Sildenafil citrate   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   4件:
51,
85,
86,
225 
 354   Sildenafil citrate (uk-92,480)   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 355   Sildenafil singly or in association with bosentan   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 356   Simvastatin   Simvastatin   D00434   1件: HMGCR   4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis   19件:
6,
13,
15,
34,
46,
49,
51,
66,
79,
86,
89,
94,
158,
162,
195,
265,
298,
299,
310 
 357   Sitaxentan   Sitaxentan   D07171   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 358   Sitaxentan sodium   Sitaxentan   D07171   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 359   Sitaxsentan   Sitaxentan   D07171   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 360   Sitaxsentan alone   Sitaxentan   D07171   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 361   Sitaxsentan and sildenafil   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 362   Sitaxsentan sodium   Sitaxentan   D07171   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 363   Slow dose titration group of subcutaneous treprostinil   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 364   Sodium nitrite   Nitrite   -   -   -   2件:
86,
299 
 365   Sodium nitrite inhalation solution   Nitrite   -   -   -   1件:
86 
 366   Sodium tanshinone iia sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 367   Sorafenib   Sorafenib   D06272, D08524   8件: BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET   83件: Acute myeloid leukemia, Alcoholism, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway   2件:
34,
86 
 368   Sotatercept   Sotatercept   D09670   1件: ACVR2A   4件: Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Signaling pathways regulating pluripotency of stem cells, TGF-beta signaling pathway   2件:
86,
284 
 369   Spironolactone   Spironolactone   D00443   1件: NR3C2   1件: Aldosterone-regulated sodium reabsorption   6件:
58,
67,
86,
113,
218,
225 
 370   Spironolactone and conivaptan   Spironolactone   D00443   1件: NR3C2   1件: Aldosterone-regulated sodium reabsorption   1件:
86 
 371   Spironolactone captopril carvedilol   Spironolactone   D00443   1件: NR3C2   1件: Aldosterone-regulated sodium reabsorption   1件:
86 
 372   Sti571   Imatinib   D01441, D08066   3件: ABL1, KIT, PDGFRA   32件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   2件:
51,
86 
 373   Subcutaneous and intravenous prostacyclin   Epoprostenol   D00106, D01337   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 374   Subcutaneous treprostinil   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 375   Sugar pill   -   -   -   -   7件:
6,
49,
67,
70,
86,
206,
226 
 376   Sulfate   Sulfate ion   -   -   -   22件:
2,
6,
11,
13,
26,
34,
36,
46,
49,
60,
61,
64,
66,
79,
86,
96,
222,
226,
265,
296,
297,
299 
 377   Tadalafil   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   6件:
6,
51,
75,
84,
86,
113 
 378   Tadalafil 20 mg film-coated tablets   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 379   Tadalafil 40 mg   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 380   Tadalafil and ambrisentan upfront combination therapy   Ambrisentan   D07077   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   2件:
51,
86 
 381   Tadalafil oral suspension   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 382   Tadalafil, placebo   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 383   Tadalafil- tablet or oral suspension   Tadalafil   D02008   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 384   Tamoxifen   Tamoxifen   D00966, D08559   2件: ESR1, ESR2   9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway   4件:
2,
86,
113,
227 
 385   Tasigna   Nilotinib   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   2件:
34,
86 
 386   Tasigna®   Nilotinib   D08953   4件: ABL1, KIT, PDGFRA, PDGFRB   33件: Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Shigellosis, Viral myocarditis   1件:
86 
 387   Tegaderm   -   -   -   -   1件:
86 
 388   Terguride   Terguride   D01348   2件: DRD2, PRL   12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway   2件:
51,
86 
 389   Terguride 0.5 mg tablet   Terguride   D01348   2件: DRD2, PRL   12件: Alcoholism, Cocaine addiction, Cytokine-cytokine receptor interaction, Dopaminergic synapse, Gap junction, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Parkinson disease, Prolactin signaling pathway, Rap1 signaling pathway, cAMP signaling pathway   1件:
86 
 390   Tezosentan   Tezosentan   -   -   -   1件:
86 
 391   The pops study is collecting pk data on children prescribed the following drugs of interest per standard of care:   -   -   -   -   1件:
86 
 392   Thelin   Sitaxentan   D07171   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
86 
 393   Threonine   L-threonine   D00041   -   -   3件:
86,
96,
97 
 394   Thrombin   Thrombin   D00090   -   -   2件:
86,
88 
 395   Tocilizumab   Tocilizumab   D02596   1件: IL6R   11件: Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease (NAFLD), PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor   16件:
2,
13,
40,
41,
43,
46,
50,
51,
53,
54,
55,
86,
107,
266,
271,
331 
 396   Traclear   -   -   -   -   1件:
86 
 397   Tracleer   Bosentan   D01227, D07538   2件: EDNRA, EDNRB   9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   8件:
13,
51,
84,
85,
86,
88,
210,
211 
 398   Tracleer®   -   -   -   -   1件:
86 
 399   Transdihydrolisuride   -   -   -   -   2件:
51,
86 
 400   Treprostin   -   -   -   -   1件:
86 
 401   Treprostinil   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   5件:
51,
84,
85,
86,
88 
 402   Treprostinil diethanolamine   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   2件:
51,
86 
 403   Treprostinil diolamine   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 404   Treprostinil inhalation powder   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 405   Treprostinil inhalations   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 406   Treprostinil injectable product   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 407   Treprostinil sodium   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   2件:
86,
88 
 408   Treprostinil sodium solution for inhalation   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 409   Treprostinil sodium, ut-15   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 410   Treprostinil, ut-15, lrx-15, 15au81, bw a15au, u-62, 840   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 411   Trimetazidine   Trimetazidine   D01606, D08642   -   -   2件:
58,
86 
 412   Trk-100stp   -   -   -   -   1件:
86 
 413   Tyrosine   Tyrosine   D00022   -   -   3件:
6,
86,
111 
 414   Tyvaso inhalation solution   -   -   -   -   1件:
86 
 415   Ubenimex   Ubenimex   D00087   1件: ANPEP   4件: Glutathione metabolism, Hematopoietic cell lineage, Metabolic pathways, Renin-angiotensin system   1件:
86 
 416   Udenafil   Udenafil   D10027   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   1件:
86 
 417   Uk-92,480   -   -   -   -   1件:
86 
 418   Uptravi   Selexipag   D09994   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 419   Ut-15c   -   -   -   -   1件:
86 
 420   Ut-15c (treprostinil diethanolamine)   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 421   Ut-15c 0.25 mg   -   -   -   -   1件:
86 
 422   Ut-15c 1 mg   -   -   -   -   1件:
86 
 423   Ut-15c 5 mg   -   -   -   -   1件:
86 
 424   Ut-15c sr   -   -   -   -   2件:
51,
86 
 425   Ut-15c sr (treprostinil diethanolamine)   Treprostinil   D06213   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 426   Vardenafil   Vardenafil   D02731, D03260, D08668   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   3件:
13,
86,
299 
 427   Ventavis   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 428   Ventavis (iloprost, bayq6256)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 429   Ventavis 10   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 430   Ventavis(iloprost)   Iloprost   D02721   1件: PTGIR   3件: Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction   1件:
86 
 431   Viagra   Sildenafil   D02229, D08514   1件: PDE5A   3件: Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway   3件:
86,
96,
225 
 432   Volibris   Ambrisentan   D07077   1件: EDNRA   7件: Calcium signaling pathway, Neuroactive ligand-receptor interaction, Pathways in cancer, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   3件:
51,
86,
88 
 433   Zamicastat   Zamicastat   -   -   -   1件:
86 

先頭へ